Oncology Voice Network
Join to access to all OVN content. Join for Free
Rethinking How We Track and Treat Cancer
diagnostic genomics breast cancer antibody drug conjugate ADC breast cancer lung cancer biomarker

Rethinking How We Track and Treat Cancer

  • Jul 13th 2025
  • 19 mins
  • Labcorp Perspectives Oncology

Share This Article

Clips

View Media
Summary

HER2, HER3, and MRD: Drs. Previs and Green break down ASCO highlights and what they mean for the future of cancer diagnostics.

Precision oncology is evolving fast, and staying ahead means rethinking how we test, monitor, and treat cancer.

In this episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs sits down with Dr. Michelle Green, senior manager of oncology genomics, to talk about the major highlights from the ASCO Annual Meeting.

They explore Labcorp’s HER2 expression study in breast cancer, which found significant changes in HER2 status over time, and what that means for retesting and clinical decisions. Michelle and Rebecca also discuss new data on HER3-targeting antibody-drug conjugates, including the potential for treating both breast and lung cancers, and advances in ctDNA testing across tumor types.

From molecular profiling to liquid biopsy, this episode provides a wide-ranging look at how new tools and emerging biomarkers are shaping the future of personalized oncology care.

Click for Source

Related Topics

See More Topics

Meet Our Innovation Partners

You May Also Like

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Mar 23rd • 10 mins • read
Article
Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China
OVN Avatar Qiyou Wu, Zhiwei Lian, Xin Wang, Hanchao Cheng, Jing Sun, Hui Yu, Gong Zhang, Fan Wu, Jian Liu and Chuanben Chen

Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China

Jan 12th • 13 mins • read
Article
Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?
OVN Avatar Neil Carleton and Priscilla F. McAuliffe

Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?

Dec 1st • 4 mins • read
Article
Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Study
OVN Avatar Min Jeong Kim, Hyo Jung Kim, Danbee Kang, Hee Kyung Ahn, Soo-Yong Shin, Juhee Cho, Yeon Hee Park,

Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Study

Oct 9th • 4 mins • read
Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Apr 26th • 15 mins • read
Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Feb 23rd • 8 mins • read

Explore OVN

Articles Expert-written insights
Browse Topics Oncology focus areas
OVN Podcast Flagship show
Community Why join OVN